Protein-losing enteropathy as a new phenotype in atypical hemolytic uremic syndrome caused by CD46 gene mutation and recovery from chronic kidney failure by eculizumab treatment

Author:

Wang Chunyan1,Chen Jing1,Han Xinli1,Sun Manqing1,Fang Xiaoyan1,Zhai Yihui1,Miao Qianfan1,Zhang Zhiqing1,Tang Xiaoshan1,Liu Jiaojiao1,Dai Rufeng1,Shen Qian1,Xu Hong1ORCID

Affiliation:

1. Children's Hospital of Fudan University

Abstract

Abstract

Background: Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathies. Genetic defects in complement alternative pathway have been identified in 60-70% of aHUS individuals. Eculizumab is recommended as first-line therapy. Methods: We collected clinical data of a pediatric aHUS case, who accompanied with protein-losing enteropathy (PLE). Genetic testing was performed. Related literatures of aHUS combined with PLE were reviewed. Results: A 15-year-old Chinese girl was diagnosed with aHUS at 3.7-year- old, and suffered with five episodes, she showed completely resolved with plasma treatment. Severe gastrointestinal symptoms and hypoalbuminemia presented after first episode and protein-losing enteropathy (PLE) was diagnosed. A novel homozygous CD46 variant was identified and FACS showed significantly decreased CD46 expression. She presented a recent relapse with persistent GI symptoms and headache, and progressed to chronic kidney failure, peritoneal dialysis was initiated. Eculizumab was given after 8 months of last recurrence. Surprisingly, PLE was cured, Afterwards, dialysis could be discontinued, eGFR recovered to 44.8ml/min/1.73㎡. Review of literatures indicated PLE with thrombosis was caused by CD55 variants with a mechanism of hyperactivation of complement system. We firstly reported an aHUS case with PLE caused by CD46 variants, both symptoms of PLE and aHUS improved significantly in our case and cases reported with CD55 variants treated with eculizumab, which indicates PLE as a new symptom of aHUS in our case with CD46 variants. Conclusions: Our case expands phenotype of aHUS caused by CD46 mutation, and provide evidence of efficiency of eculizumab after a long chronic kidney failure phase.

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3